

Please type a plus sign (+) inside this box.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
ANFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>2002 4 4 4</small> (use as many sheets as necessary)			
Serial	1	of	2
		Application Number	10/044,716
		Filing Date	January 11, 2002
		First Named Inventor	John Langenfeld
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	270/070



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SECRET 1 of 2

~~RECEIVED~~

JUN 28 2002

TECH CENTER 1600/1900

FOREIGN PATENT DOCUMENTS

Examiner Signature	<u>J. R.</u>	Date Considered	4/7/05
--------------------	--------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>O SCA JUN 25 2002 (use as many sheets as necessary)</small>		Application Number	10/044,716
		Filing Date	January 11, 2002
		First Named Inventor	John Langenfeld
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	270/070


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S'Hz	AH	HATAKEYAMA, S. et al., "Expression of Bone Morphogenetic Proteins of Human Neoplastic Epithelial Cells", Biochem. Mol. Biol. Int., 1997, pp. 497, Vol. 497	
	AI	KLEEFF, Jorg et al., Bone Morphogenetic Protein 2 Exerts Diverse Effects on Cell Growth In Vitro and Is Expressed in Human Pancreatic Cancer In Vivo, Gastroenterology, May 1999, pp. 1202-1216, Vol. 116, No. 5, University of California, Irvine, California	
	AJ	GUO, W. et al., "Expression of Bone Morphogenetic Proteins and Receptors In Sarcomas", Clin. Orthop., 1999, pp. 175-83, Vol. 365	

~~RECEIVED~~

JUN 28 2002

TECH CENTER 1600/2900


Examiner Signature		Date Considered	4/7/08
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1449		ATTY. DOCT. NO. 272/070US	SERIAL NO. 10/044,716
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Langenfeld, John	
		FILING DATE: 01/11/02	GROUP: 1645



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	
AA							
AB						RECEIVED	
AC						JUL 11 2002	
AD							
AE						TECH CENTER 1600/2900	
AF							
AG							
AH							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	NO
AI							
AJ							
AK							

NON PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
SH	AL	Abe et al., "Essential Requirement of BMPs-2/4 for Both Osteoblast and Osteoclast Formation in Murine Bone Marrow Cultures from Adult Mice: Antagonism by Noggin," J. of Bone and Mineral Res., Vol. 15, No. 4, (2000) pp. 663-673
	AM	An et al., "Recombinant Human Bone Morphogenetic Protein-2 Induces a Hematopoietic Microenvironment in the Rat that Supports the Growth of Stem Cells," Experimental Hematology, Vol. 24, (1996) pp. 768-775
	AN	Celeste et al., "Identification of Transforming Growth Factor β Family Members Present in Bone-Inductive Protein Purified From Bovine Bone," Proc. Natl. Acad. Sci. USA, Vol. 87, (1990), pp. 9843-9847
7	AO	Cui et al., "BMP-4 is Proteolytically Activated by Furin and/or PC6 During Vertebrate Embryonic Development," The EMBO Journal, Vol. 17, No. 16, (1998), pp.4735-4743

EXAMINER: Not Yet Assigned	<i>LC</i>	DATE CONSIDERED: 4/7/08
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant		

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:

Langenfeld, John

JUL 05 2002

FILING DATE:

01/11/02

GROUP:

1645

RECEIVED

TECH CENTER 1800/2

J2	AP	Cunningham et al., "Osteogenin and Recombinant Bone Morphogenetic Protein 2B are Chemotactic for Human Monocytes and Stimulate Transforming Growth Factor β 1 mRNA Expression," Proc. Natl. Acad. Sci. USA, Vol. 89, (1992), pp. 11740-11744
	AQ	Erickson et al., "Recombinant Bone Morphogenetic Protein (BMP)-2 Regulates Costochondral Growth Plate Chondrocytes and Induces Expression of BMP-2 and BMP-4 in a Cell Maturation-Dependent Manner," J. of Orthopaedic Research, Vol. 15, (1997) pp. 371-380
	AR	Liu et al., "Human Type II Receptor for Bone Morphogenic Proteins (BMPs): Extension of the Two-Kinase Receptor Model to the BMPs." Molecular and Cellular Biology, Vol. 15, No. 7, (1995), pp. 3479-3486
	AS	Sakou et al., "Localization of Smads, the TGF- β Family Intracellular Signaling Components During Endochondral Ossification," J. of Bone and Mineral Res., Vol. 14, No. 7, (1999), pp. 1145-1152
	AT	ten Dijke et al., "Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4," J. of Bio. Chem., Vol. 269, No. 25, (1994), pp. 16985-16988
	AU	Vainio et al., "Identification of BMP-4 as a Signal Mediating Secondary Induction Between Epithelial and Mesenchymal Tissues During Early Tooth Developmental," Cell, Vol. 75, 1993, pp. 45-48
	AV	Warburton et al., "The Molecular Basis of Lung Morphogenesis," Mechanism of Development, Vol. 92, (2000), pp. 55-81
	AW	Weaver et al., "BMP Signaling Regulates Proximal-Distal Differentiation of Endothelium in Mouse Lung Development," Development, Vol. 126 (1999), pp. 4005-4015
	AX	Willette et al., "BMP-2 Gene Expression and Effects on Human Vascular Smooth Muscle Cells," J. of Vascular Research, Vol. 36, (1999), pp. 120-125
▼	AY	Wozney et al., "Novel Regulators of Bone Formation: Molecular Clones and Activities," Science, Vol. 242, (1988), pp. 1528-1534

EXAMINER:
Not Yet Assigned

DATE CONSIDERED:

8/7/05

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include a copy of this form with
next communication to applicant

FORM PTO-1449 <i>C.I.P.</i> LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT AUG 12 2002 PATENTS & TRADEMARK OFFICE (Use several sheets if necessary)		ATTY. DOCKET NO. 272/070US	SERIAL NO. 10/044,716
		APPLICANT: Langenfeld, John	
		FILING DATE: January 11, 2002	GROUP: 1645

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC			COPY OF PAPERS ORIGINALLY FILED			
	AD						
	AE						
	AF						
	AG						
	AH						

*RECEIVED
AUG 14 2002
TECH CENTER 1600/2900*

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						

NON PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
SR	AL	Ikeda et al., "Cloning of Rat Type I Receptor cDNA for Bone Morphogenetic Protein-2 and Bone Morphogenetic Protein-4, and the Localization Compared With That of the Ligands," Developmental Dynamics, Vol. 206, (1996) pp. 318-329
SR	AM	ten Dijke et al., "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity," Oncogene, Vol. 8, (1993) pp. 2879-1887
	AN	
	AO	

LA-242662.1

EXAMINER:	<i>[Signature]</i>	DATE CONSIDERED: <i>4/7/08</i>
-----------	--------------------	--------------------------------

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant